# US 10,870,641 B2 · Pyridazinones as PARP7 inhibitors > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 10,870,641 B2 - Document ID: US10870641B2 - Status: Granted - Kind: B2 - Application number: 16/662,409 - Filed: 2019-10-24 - Published: 2020-04-23 - Granted: 2020-12-22 - Earliest claimed: 2018-04-30 - Assignees: Ribon Therapeutics, Inc. - Applicants: Ribon Therapeutics Inc. - Inventors: Melissa Marie Vasbinder; Laurie B. Schenkel; Kerren Kalai Swinger; Kevin Wayne Kuntz - Web page: https://patentgrep.com/patent/US10870641B2 ## CPC - C07D 403/14: containing three or more hetero rings - A61P 35/00: Antineoplastic agents - C07D 401/12: linked by a chain containing hetero atoms as chain links - C07D 401/14: containing three or more hetero rings - C07D 403/04: directly linked by a ring-member-to-ring-member bond - C07D 403/12: linked by a chain containing hetero atoms as chain links - C07D 405/14: containing three or more hetero rings - C07D 413/14: containing three or more hetero rings - C07D 417/12: linked by a chain containing hetero atoms as chain links - C07D 417/14: containing three or more hetero rings - C07D 451/02: containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof - C07D 471/04: Ortho-condensed systems - C07D 471/08: Bridged systems - C07D 471/10: Spiro-condensed systems - C07D 487/04: Ortho-condensed systems - C07D 487/08: Bridged systems - C07D 487/10: Spiro-condensed systems - C07D 495/04: Ortho-condensed systems - C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08) - A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS ## Abstract The present invention relates to pyridazinones and related compounds which are inhibitors of PARP7 and are useful in the treatment of cancer. ## Claims ### Claim 1 A method of treating cancer in a patient in need of treatment comprising administering to said patient a therapeutically effective amount of a compound having the structure: or a pharmaceutically acceptable salt thereof, wherein said cancer is breast cancer, cancer of the central nervous system, endometrium cancer, kidney cancer, large intestine cancer, lung cancer, oesophagus cancer, ovarian cancer, pancreatic cancer, prostate cancer, stomach cancer, head and neck cancer (upper aerodigestive cancer), urinary tract cancer, or colon cancer. ### Claim 2 (depends on 1) The method of claim 1 wherein said cancer is lung cancer. ### Claim 3 (depends on 1) The method of claim 1 wherein said cancer is breast cancer. ### Claim 4 (depends on 1) The method of claim 1 wherein said cancer is cancer of the central nervous system. ### Claim 5 (depends on 1) The method of claim 1 wherein said cancer is endometrium cancer. ### Claim 6 (depends on 1) The method of claim 1 wherein said cancer is kidney cancer. ### Claim 7 (depends on 1) The method of claim 1 wherein said cancer is large intestine cancer. ### Claim 8 (depends on 1) The method of claim 1 wherein said cancer is oesophagus cancer. ### Claim 9 (depends on 1) The method of claim 1 wherein said cancer is ovarian cancer. ### Claim 10 (depends on 1) The method of claim 1 wherein said cancer is pancreatic cancer. ### Claim 11 (depends on 1) The method of claim 1 wherein said cancer is prostate cancer. ### Claim 12 (depends on 1) The method of claim 1 wherein said cancer is stomach cancer. ### Claim 13 (depends on 1) The method of claim 1 wherein said cancer is head and neck cancer (upper aerodigestive cancer). ### Claim 14 (depends on 1) The method of claim 1 wherein said cancer is urinary tract cancer. ### Claim 15 (depends on 1) The method of claim 1 wherein said cancer is colon cancer. ### Claim 16 A method of treating cancer in a patient in need of treatment comprising administering to said patient a therapeutically effective amount of a compound having the structure: or a pharmaceutically acceptable salt thereof, wherein said cancer is breast cancer, cancer of the central nervous system, endometrium cancer, kidney cancer, large intestine cancer, lung cancer, oesophagus cancer, ovarian cancer, pancreatic cancer, prostate cancer, stomach cancer, head and neck cancer (upper aerodigestive cancer), urinary tract cancer, or colon cancer. ### Claim 17 (depends on 16) The method of claim 16 wherein said cancer is lung cancer. ### Claim 18 (depends on 16) The method of claim 16 wherein said cancer is breast cancer. ### Claim 19 (depends on 16) The method of claim 16 wherein said cancer is cancer of the central nervous system. ### Claim 20 (depends on 16) The method of claim 16 wherein said cancer is endometrium cancer. ### Claim 21 (depends on 16) The method of claim 16 wherein said cancer is kidney cancer. ### Claim 22 (depends on 16) The method of claim 16 wherein said cancer is large intestine cancer. ### Claim 23 (depends on 16) The method of claim 16 wherein said cancer is oesophagus cancer. ### Claim 24 (depends on 16) The method of claim 16 wherein said cancer is ovarian cancer. ### Claim 25 (depends on 16) The method of claim 16 wherein said cancer is pancreatic cancer. ### Claim 26 (depends on 16) The method of claim 16 wherein said cancer is prostate cancer. ### Claim 27 (depends on 16) The method of claim 16 wherein said cancer is stomach cancer. ### Claim 28 (depends on 16) The method of claim 16 wherein said cancer is head and neck cancer (upper aerodigestive cancer). ### Claim 29 (depends on 16) The method of claim 16 wherein said cancer is urinary tract cancer. ### Claim 30 (depends on 16) The method of claim 16 wherein said cancer is colon cancer.